source
- Regenxbio reports positive Duchenne gene therapy trial results, targets FDA approval by 2027Regenxbio announced that its gene therapy for Duchenne muscular dystrophy achieved the required endpoints in a pivotal clinical trial. The data met the study's predefined criteria, which the compa…
- CREATE Medicines raises $122 million to advance CAR-T candidates into human trialsCREATE Medicines, formerly Myeloid Therapeutics, announced a $122 million financing round. The funding came from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners and other invest…